In a report released today, Mark Mahaney from Evercore ISI maintained a Buy rating on Ibotta, Inc. Class A (IBTA – Research Report), with ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Innate Pharma (IPHA – Research Report) today and set a price target of $5.00.

Sarah Bianchi, Evercore ISI chief strategist of public policy, joins CNBC's 'The Exchange' to discuss the so-called DOGE ...

Capri and Tapestry have mutually agreed to terminate their planned merger. Capri CEO continues to see long-term potential in ...

Krishna Guha, Evercore ISI vice chairman, joins CNBC's 'Squawk Box' to discuss expectations for PPI, how a new Trump ...

Investing.com - A "strong case" can be made for a re-valuation higher of the life insurance sector, according to analysts at ...

Evercore ISI initiates negative call on Target Corporation (TGT) ahead of earnings report, forecasting Q3 sales deceleration ...

Evercore ISI revised its ratings for several industrial and machinery stocks following the US election results, citing a more optimistic business outlook tied to the anticipated "pro-business Trump" ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Sunrun (RUN), and SolarEdge (SEDG) — are trailing behind in the days following Donald Trump's 2024 election victory. The sector was considered a part of the "Harris Trade" attributed to the ...